FDA approves AI-powered breast cancer screening tool

An AI application that aids early stage breast cancer screening has been approved by the US Food and Drug Administration for commercialization, software developer MedCognetics announced this week.

MedCognetics, based in Texas, has built a cloud-based software-as-a-service system for radiologists that analyzes mammograms. The systems runs QmTRIAGE, the company's breast cancer screening tool, which just received 510 clearance from the FDA. QmTRIAGE is powered by computer vision algorithms trained to estimate the density of breast tissue to detect things like cysts or tumors associated with cancer in mammography scans. Radiologists have to scrutinize these scans carefully to determine whether a patient requires a follow-up biopsy to test for breast cancer. MedCognetics believes its tool will aid radiologists by highlighting breast tissue that needs further examination.

"It will help with cost and time savings, reducing the amount of time a radiologist needs to review a case by 30 to 50 percent," MedCognetics' CEO, Debasish 'Ron' Nag, claimed in a statement to. This is an important factor, given that demand for radiologists vastly outpaces supply, and burnout in the profession is rampant.

"The vast majority of early stage cancers do not present with any clinical signs – they are detected on a screening mammogram before the woman has any symptoms. The only cure to breast cancer today is early detection. To enable that you need to see beyond the naked eye, and this is what MedCognetics does," he added.

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Mum dies after being given cancer diagnosis same day she gave birth to daughterKaryn Love, 39, only had 19 short months with her daughter before she died from breast cancer this week.
Source: Daily_Record - 🏆 9. / 89 Read more »

Phosphoproteomic analysis of neoadjuvant breast cancer suggests that increased sensitivity to paclitaxel is driven by CDK4 and filamin A - Nature CommunicationsPhosphoproteomics is a promising tool for identifying biomarkers of treatment response in cancer. Here, the authors analyse proteomics profiling of HER2-negative female breast cancer patients and identify potential predictors of paclitaxel response. physorg_com NatureComms Now if they could just mitigate the destruction of the ovaries.
Source: medical_xpress - 🏆 101. / 51 Read more »